Age-related macular degeneration 12

Common Name(s)

Age-related macular degeneration 12

Description for this condition is not yet available.
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Age-related macular degeneration 12" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Age-related macular degeneration 12" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Age-related macular degeneration 12" returned 6 free, full-text research articles on human participants. First 3 results:

Prospective audit of exudative age-related macular degeneration: 12-month outcomes in treatment-naive eyes.
 

Author(s): Mark C Gillies, Richard Walton, Judy M Simpson, Jennifer J Arnold, Robyn H Guymer, Ian L McAllister, Alex P Hunyor, Rohan W Essex, Nigel Morlet, Daniel Barthelmes,

Journal:

 

We report the 12-month outcomes of 1140 treatment-naïve eyes with exudative age-related macular degeneration (wet AMD) who were treated for 12 months with intravitreal anti-VEGF drugs in routine clinical practice.

Last Updated: 28 Aug 2013

Go To URL
Homocysteine, folate, vitamin B-12, and 10-y incidence of age-related macular degeneration.
 

Author(s): Bamini Gopinath, Victoria M Flood, Elena Rochtchina, Jie Jin Wang, Paul Mitchell

Journal: Am. J. Clin. Nutr.. 2013 Jul;98(1):129-35.

 

Epidemiologic evidence of a relation between serum total homocysteine (tHcy), vitamin B-12, and folate and age-related macular degeneration (AMD) is inconsistent and unresolved.

Last Updated: 21 Jun 2013

Go To URL
Effectiveness of ranibizumab intravitreal injections for exudative age-related macular degeneration treatment: 12-month outcomes.
 

Author(s): Figurska Małgorzata, Andrzej Stankiewicz

Journal: Med. Sci. Monit.. 2011 Sep;17(9):CR485-90.

 

The aim of this paper was to evaluate functional and anatomical results of intravitreal ranibizumab injections and the course of exudative age-related macular degeneration (AMD) treatment over a 12-month observation period.

Last Updated: 29 Aug 2011

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Age-related macular degeneration 12" returned 0 free, full-text review articles on human participants.

 
 
Top

Symptoms, Diagnosis, and Treatment

There are currently no related results available in GeneReviews.

 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Eylea to Treat Retinal Pigment Epithelial Detachment (RPED) Secondary to Wet Age-Related Macular Degeneration (wAMD)
 

Status: Not yet recruiting

Condition Summary: Retinal Pigment Epithelial Detachment Secondary to Age-related Macular Degeneration

 

Last Updated: 19 May 2014

Go to URL
Randomized Study for Efficacy and Safety of Ranibizumab 0.5mg in Treat-extend and Monthly Regimens in Patients With nAMD
 

Status: Recruiting

Condition Summary: Age-related Macular Degeneration; Choroidal Neovascularization

 

Last Updated: 5 Jun 2014

Go to URL
Safety and Tolerability of Ranibizumab in Mono/Bilateral w-AMD Patients in Eyes With BCVA<2/10 and/or 2nd Affected Eye
 

Status: Recruiting

Condition Summary: Wet Age Related Macular Degeneration

 

Last Updated: 28 May 2014

Go to URL